Stilbene derivatives and their use for binding and imaging amyloid plaques
View Patent ↗This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
1. A compound of general Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
R 28 is hydrogen or C 1-4 alkyl,
n is equal to a number from zero to four,
Z is —CR 15 ═CR 16 —, wherein
R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from the group consisting of:
a. hydrogen
b. C 1-4 alkylthio,
c. hydroxy,
d. C 1-4 alkoxy,
e. NR 26 R 27 , wherein
R 26 and R 27 are hydrogen or C 1-4 alkyl,
f. phenyl(C 1-4 )alkyl,
g. C 6-10 aryl,
h. heteroaryl,
i. heterocycle,
j. heterocycle(C 1-4 )alkyl, and
k. C 3-6 cycloalkyl,
wherein said phenyl(C 1-4 )alkyl, C 6-10 aryl, heteroaryl, heterocycle, heterocycle(C 1-4 )alkyl or C 3-6 cycloalkyl is substituted with one of the following: C 1-4 alkylthio, C 1-4 alkyl, methoxy, hydroxy, dimethylamino or methylamino;
provided that one or more of R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 and R 25 is other than hydrogen; and,
R P is hydrogen or a sulfur protecting group.
2. A compound of claim 1 , wherein
R 17 is NR 26 R 27 wherein
R 26 and R 27 are as described above, and
R 15 , R 16 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 and R 28 are hydrogen.
3. A compound of claim 1 , wherein n is equal to zero.
4. A compound of claim 1 , wherein R 26 and R 27 are independently hydrogen or C 1-4 alkyl.
5. A compound of claim 4 , wherein R 26 and R 27 are methyl.
6. A compound of general Formula V:
or a pharmaceutically acceptable salt thereof, wherein:
R is, in each instance, independently selected from the group consisting of:
a. C 1-4 alkylthio,
b. halo(C 1-4 )alkoxy,
c. carboxy(C 1-5 )alkyl,
d. hydroxy,
e. C 1-4 alkoxy,
f. NR 36 R 37 , wherein
R 36 and R 37 are hydrogen, fluoro(C 1-4 )alkyl or C 1-4 alkyl,
g. phenyl(C 1-4 )alkyl,
h. C 6-10 aryl,
i. heteroaryl,
j. heterocycle,
k. heterocycle(C 1-4 )alkyl,
l. C 3-6 cycloalkyl,
wherein said phenyl(C 1-4 )alkyl, C 6-10 aryl, heteroaryl, heterocycle, heterocycle(C 1-4 )alkyl or C 3-6 cycloalkyl is substituted with one of the following: C 1-4 alkylthio, C 1-4 alkyl sulfonyl, methoxy, hydroxy, dimethylamino or methylamino, and
m. alkyl; and
R P is hydrogen or a sulfur protecting group.
7. A compound of claim 6 , wherein said protecting group is selected from the group consisting of methoxymethyl, methoxyethoxymethyl, p-methoxybenzyl or benzyl.
8. A pharmaceutical composition comprising a compound of claim 1 .
9. A compound having the following structure:
or a pharmaceutically acceptable salt thereof, wherein:
R 28 and R 28 are each independently hydrogen or C 1-4 alkyl, —Ch is a N 2 S 2 -type metal chelating moiety,
R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 and R 25 are independently selected from the group consisting of:
a. hydrogen
b. C 1-4 alkylthio,
C. hydroxy,
d. C 1-4 alkoxy,
e. NR 26 R 27 , wherein
R 26 and R 27 are hydrogen or C 1-4 alkyl,
f. phenyl(C 1-4 )alkyl,
g. C 6-10 aryl,
h. heteroaryl,
i. heterocycle,
j. heterocycle(C 1-4 )alkyl, and
k. C 3-6 cycloalkyl,
wherein said phenyl(C 1-4 )alkyl, C 6-10 aryl, heteroaryl, heterocycle, heterocycle(C 1-4 )alkyl or C 3-6 cycloalkyl is substituted with one of the following: C 1-4 alkylthio, C 1-4 alkyl, methoxy, hydroxy, dimethylamino or methylamino;
provided that one or more of R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 and R 25 is other than hydrogen.
10. The compound of claim 9 , one or more of R 15 , R 16 , R 18 , R 19 , R 20 , R 21 , and R 17 is hydroxy or NR 26 R 27 , wherein R 26 and R 27 are hydrogen or C 1-4 alkyl.